Osteoporosis
Drug research and approvals for osteoporosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 120 studies of osteoporosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 35 authorised medicines for it.
- Recruiting worldwide: 120
- Trials authorized in Canada: 7
- FDA orphan approvals: 1
- EU medicines: 35
Recruiting Now
Newest start dates first, of 120 recruiting on ClinicalTrials.gov ↗- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,…NCT07083557 · Not reported · Bettina Mittendorfer · starts Jan 1, 2027
- Post-osteoporotic Fracture Exercise ProgramNCT07595991 · Not applicable · Western University, Canada · starts Dec 1, 2026
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
- A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment…NCT07920484 · Not reported · Amber Implants B.V. · starts Oct 4, 2026
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab DiscontinuationNCT07406685 · Phase 4 · National Taiwan University Hospital · starts Aug 20, 2026
- A Study of Romosozumab in People With Breast Cancer and OsteoporosisNCT07776613 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Aug 17, 2026
- Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal FemalesNCT07365514 · Phase 1 · University of Connecticut · starts Jul 1, 2026
- REMS vs DXA for Osteoporosis Diagnosis and Fracture Risk PredictionNCT07876882 · Not reported · BoneVue Diagnostics · starts Jun 24, 2026
- Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?NCT07677072 · Not reported · Kanuni Sultan Suleyman Training and Research Hospital · starts May 15, 2026
- People With Osteoporosis Can Walk-BEST to Reduce Fall and Fracture RiskNCT07621679 · Not applicable · McGill University Health Centre/Research Institute of the McGill University Health Centre · starts May 7, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 16, 2022 | Efficacy of a single infusion of zoledronic acid to mitigate the rebound effect of rapid bone loss following denosumab treatment discontinuationZOLEDRONIC ACID | GOVERNORS OF THE UNIVERSITY OF CALGARY | Pending |
| Mar 6, 2019 | A randomized, double-blind, placebo-controlled, phase 3 multicenter study to evaluate the safety and efficacy of abaloparatide-sc for the treatment of men with…ABALOPARATIDE (BA058) | Radius Health | Closed |
| Jul 21, 2017 | A phase 3 randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of denosumab in pediatric subjects with…PROLIA | Amgen | Ongoing |
| Jun 7, 2017 | The efficacy and safety of rosuvastatin for modifying bone mass and cardiometabolic disease outcomes (robaco trial)ROSUVASTATIN | DR BEVERLY CATHARINE CRAVEN | Ongoing |
| Jan 7, 2016 | A single-blinded, randomized, controlled, phase 2 pilot study to evaluate the safety and efficacy of denosumab compared to zoledronic acid for the treatment of…PROLIA / ZOLEDRONIC ACID | CHILDRENS HOSPITAL OF EASTERN ONTARIO | Closed |
| May 14, 2014 | Risedronate in chronic kidney disease (rick): a randomized controlled pilot studyRISEDRONATE | WOMENS COLLEGE HOSPITAL | Pending |
| Feb 5, 2014 | A multicenter, double-blind, randomized study to assess the efficacy and safety of denosumab produced by two different processess in postmenopausal women with…PROLIA (DENOSUMAB) | Amgen | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Sep 13, 2007 | EvistaReduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in… | Eli Lilly and Company | Approved |
| Oct 28, 1999 | TeriparatideTreatment of idiopathic osteoporosis. | Biomeasure, Inc. | Designated |
Medicines Authorised in the EU
Newest first; 15 of 35| Apr 27, 2026 | Zandoriahteriparatide · biosimilar | CinnaGen Co Unipessoal LDA | EMA ↗ |
| Jan 8, 2026 | Osqaydenosumab · biosimilar | Theramex Ireland Limited | EMA ↗ |
| Nov 17, 2025 | Kefdensisdenosumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Nov 17, 2025 | Acvybradenosumab · biosimilar | Reddy Holding GmbH | EMA ↗ |
| Nov 17, 2025 | Vysribli (previously Denosumab Intas)Vysribli · biosimilar | Intas Third Party Sales 2005 S.L. | EMA ↗ |
| Nov 17, 2025 | Ponlimsidenosumab · biosimilar | Teva GmbH | EMA ↗ |
| Sep 17, 2025 | Bildyosdenosumab · biosimilar | Sciencepharma Sp. z o.o | EMA ↗ |
| Jul 18, 2025 | Conexxencedenosumab · biosimilar | Fresenius Kabi Deutschland GmbH | EMA ↗ |
| Jul 17, 2025 | Rolcyadenosumab · biosimilar | Sandoz GmbH | EMA ↗ |
| Jun 30, 2025 | Evfraxydenosumab · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Jun 26, 2025 | Zadenvidenosumab · biosimilar | Zentiva k.s. | EMA ↗ |
| Jun 26, 2025 | Izambydenosumab · biosimilar | Mabxience Research SL | EMA ↗ |
| Jun 23, 2025 | Junoddenosumab · biosimilar | Gedeon Richter Plc. | EMA ↗ |
| May 26, 2025 | Osvyrtidenosumab · biosimilar | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 14, 2025 | Stoboclodenosumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA